A phase 3b study of sofosbuvir plus ribavirin in Taiwanese patients with chronic genotype 2 hepatitis C virus infection
Jia‐Horng Kao(National Taiwan University Hospital), Wan‐Long Chuang(Kaohsiung Medical University), Steven Knox(Gilead Sciences (United States)), Rong‐Nan Chien(Chang Gung Memorial Hospital), Tsung‐Hui Hu(National Sun Yat-sen University), Anita Mathias(Gilead Sciences (United States)), Cheng‐Yuan Peng(China Medical University), Horng‐Yuan Wang(Mackay Memorial Hospital), Jenny C. Yang(Gilead Sciences (United States)), Gin‐Ho Lo(E-Da Hospital), Lingling Han(Gilead Sciences (United States)), Yu‐Chun Hsu(The University of Texas Health Science Center at Houston), Chi‐Jen Chu(Taipei Veterans General Hospital), Diana M. Brainard(Gilead Sciences (United States)), Ting‐Tsung Chang(National Cheng Kung University Hospital), Hongmei Mo(Gilead Sciences (United States)), I‐Shyan Sheen(Chang Gung University), Jyh‐Jou Chen(Tainan University of Technology)
Cited by 29
Related Papers
Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study
|The Lancet. Gastroenterology & hepatology|2016|2k
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
|New England Journal of Medicine|2013|1.8k
Mitotic and G <sub>2</sub> Checkpoint Control: Regulation of 14-3-3 Protein Binding by Phosphorylation of Cdc25C on Serine-216
|Science|1997|1.3k
Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options
|New England Journal of Medicine|2013|1.1k
Long-term Therapy With Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B for up to 5 Years
|Gastroenterology|2006|882